The Motley Fool’s health-care show Market Checkup focuses this week on diabetes, one of America’s growing health-care concerns. There are two versions of this chronic disease, the more prevalent being type 2 diabetes, which makes up about 95% of all cases. Because of the overwhelming patient population, type 2 diabetes receives the majority of attention from Big Pharma companies.
Diabetes is no small problem. In 2010, one in 10 adults had diabetes, and more troubling, more than one in four senior citizens suffered from it. Diabetes is the seventh leading cause of death, and there are 2 million new cases in America every year, leading analysts to project spending on diabetes to approach $60 billion in just five years. And this isn’t just an American problem: 370 million suffer from diabetes around the world.
In this video, health-care analysts David Williamson and Max Macaluso discuss the cutting edge of insulin treatments, including a new inhalable insulin in development by MannKind. Shares of the biotech went on a huge run before its latest phase 3 trial results. Watch and learn about the history of inhaled insulin, along with David and Max’s thoughts about whether investors should hop on MannKind’s bandwagon or be careful with this biotech run-up.
Top 5 Information Technology Stocks To Watch Right Now: Titan Pharmaceuticals Inc (TTNP.OB)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson’s disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson’s disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine is the first product to utilize the Company’s ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine is a cell-based therapeutic that utilizes the Company’s cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson’s disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson’s disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson’s disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson’s disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company’s corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
- [By C.R. Jackson]
Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France’s Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.
Top 5 Information Technology Stocks To Watch Right Now: First Trust Ise Global Engineering And Construction Index Fund (FLM)
First Trust ISE Global Engineering and Construction Index Fund (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the ISE Global Engineering and Construction Index (the Index). The Fund is a series of the First Trust Exchange-Traded Fund II, an investment company and an exchange-traded index fund. The Index is developed and owned by the International Securities Exchange, LLC (ISE or Index Provider), in consultation with Standard & Poor’s, a Division of The McGraw-Hill Companies, Inc., which calculates and maintains the Index. The Index specifically targets companies that are engaged in civil and capital projects, such as infrastructure, utilities, transportation, telecommunications, commercial, residential and commerce facilities, and whose roles are within the engineering, designing, planning, consulting, project managing and/or constructing of these projects. First Trust Advisors L.P. is the investment adviser for the Fund. Advisors’ Opinion:
- [By John Udovich]
Small cap building materials stock NCI Building Systems Inc (NYSE: NCS) fell yesterday after announcing a share offering plus its investors have (so-far) missed out on any “recovery” in construction – meaning it might be time to take a closer look at the stock along with potential performance benchmarks like the PowerShares Dynamic Building & Construction ETF (NYSEARCA: PKB) and the First Trust ISE Global Engineering and Construction Index Fund ETF (NYSEARCA: FLM) – both of which have had decent returns in recent years.
Top 5 Information Technology Stocks To Watch Right Now: Societe Libanaise des Ciments Blancs SAL (CBN)
Societe Libanaise des Ciments Blancs SAL is a Lebanon-based joint stock company that operates in the construction materials industry sector. The Company is engaged in the production and sale of white cement. The Company is a 65.99% owned by Holcim (Liban) SAL. Advisors’ Opinion:
- [By CanadianValue]
Nigeria’s reformed banking system has provided many foreigners with an attractive means to invest in the fast-growing domestic economy. The banking industry is important, not only because of the rise of microfinance, but because of the move by banks into consumer banking. Until recently, banks were mainly financing large businesses or the government through bond purchases. Following a banking crisis in 2008, the Central Bank of Nigeria (CBN) conducted an audit of the commercial banking sector. All banks that failed the audit had their CEOs replaced. The state-owned Asset Management Corporation (AMCON) was created to purchase non-performing loans and recapitalize the unhealthy banks. A recent review of the country’s banks by the IMF showed a dramatic increase in profits for the industry in 2012, while the capital adequacy ratio was above the minimum requirement of 10% and non-performing loans were below the mandated threshold of 5%5.
Top 5 Information Technology Stocks To Watch Right Now: AVX Corp (AVX)
AVX Corporation (AVX), incorporated on September 19, 1989, is a manufacturer and supplier of a broad line of passive electronic components and related products. All types of electronic devices use AVX’s passive component products to store, filter or regulate electric energy. The Company’s passive electronic component products include ceramic and tantalum capacitors, film capacitors, varistors, filters and other components manufactured in its facilities throughout the world and passive components manufactured by Kyocera Corporation of Japan (Kyocera). It also manufactures and sells electronic connectors and inter-connect systems and distribute and sell certain electronic connectors manufactured by Kyocera. It is organized by product line with five main product groups. AVX operates in three segments: Passive Components, Kyocera Electronic Devices (KED Resale) and Interconnect. On February 6, 2013, it acquired tantalum solid electrolytic capacitor related businesses from NICHICON CORP.
through manufacturing representatives and independent electronic component distributors. The Passive Components segment consists primarily of surface mount and leaded ceramic capacitors, radio frequency (RF) thick and thin film components, tantalum capacitors, film capacitors, ceramic and film power capacitors, super capacitors, electromagnetic interference (EMI) filters, thick and thin film packages, varistors, thermistors, inductors and resistive products. The KED Resale segment consists primarily of ceramic capacitors, frequency control devices, surface acoustic wave (SAW) devices, sensor products, RF modules, actuators, acoustic devices and connectors produced by Kyocera, and resold by AVX. The Interconnect segment consists primarily of AVX Interconnect (formerly Elco) automotive, telecom and memory connectors manufactured by AVX.
AVX manufactures a range of multi-layered ceramic and solid tantalum capacitors in many different sizes and configurations. The C! ompany also offers a line of advanced passive component products to fill the special needs of the customers. Its family of passive components also includes film capacitors, high energy/voltage power capacitors, and varistors. Its advanced products engineers work with some customers’ in-house technical staffs to design, produce, and manufacture customized products to meet the specifications of particular applications. Sales of advanced products accounted for approximately 41% of passive component net sales during the fiscal year ended March 31, 2013 (fiscal 2013).
AVX has a non-exclusive license to distribute and sell certain Kyocera manufactured electronic component and connector products to certain customers and in certain territories outside of Japan. The Company’s distribution and sale of certain Kyocera products broadens its range of products and further facilitates its ability to offer one-stop shopping for the customers’ electron ic components needs. The Kyocera KDP and KKC electronic components it sells include ceramic capacitors, RF modules, frequency control devices, SAW devices, sensor products, actuators, and acoustic devices. Resale product sales also include connectors manufactured by Kyocera. Sales of these products accounted for approximately 31% of net sales in fiscal 2013.
AVX manufactures and sells electronic connectors and interconnect systems for use in the telecommunications, information technology hardware, automotive electronics, medical device, defense and aerospace industries. The Company’s product lines include a range of industry-standard connectors, as well as products designed specifically for the customers’ applications. It produces fine pitch connectors used in portable devices, such as smart phones, other cell phones, notebook computers, global positioning system (GPS), and other hand held devices. In addition, it offers specialty c onnectors designed to address customer specific applications! across a! range of products and end markets. Approximately 33% of combined Interconnect and KEC Resale Connector net sales in fiscal 2013 consisted of connectors manufactured by Kyocera.
The Company competes with Murata Manufacturing Company Ltd, TDK Corporation, KEMET Corporation, NEC Corporation, Yageo Corporation, Taiyo Yuden Co. Ltd., Samsung Electro-Mechanics, Vishay Intertechnology, Inc., Tyco Electronics, Amphenol, Molex Incorporated, FCI and Erni Electronics.
- [By Ben Levisohn]
Competitor AVX Corp. (AVX) has gained 1.1% to $12.96, while Molex (MOLX) has dropped 0.2% to $29.28 and Amphenol (APH) has ticked up 0.3% to $76.32.
Top 5 Information Technology Stocks To Watch Right Now: Cleantech Solutions International Inc (CLNT)
Cleantech Solutions International, Inc., incorporated on June 24, 1987, manufactures and sells forged products and fabricated products to a range of clean technology customers, including forged rolled rings and related products for the wind power industry and other industries and equipment to the solar industry. The Company also makes textile dyeing and finishing machines. The Company is owner of Fulland Limited (Fulland). Fulland owns 100% of Green Power Environment Technology (Shanghai) Co., Ltd. (Green Power) and Wuxi Fulland Wind Energy Equipment Co., Ltd. (Fulland Wind Energy), which are wholly foreign-owned enterprises (WFOE) organized under the laws of the People’s Republic of China. Green Power is a party to a series of contractual arrangements with Wuxi Huayang Electrical Power Equipment Co., Ltd. (Electrical) and Wuxi Huayang Dyeing Machinery Co., Ltd. (Dyeing). Dyeing produces and sells a range of high and low temperature dyeing and finishing machinery for the textile industry. The Company refers to this segment as the dyeing division. The Company is engaged in two business segments: the forged rolled rings and related components segment, in which it manufacture and sell forged rolled rings, yaw bearings and shafts, and other forged components for the wind power and other industries, as well as equipment for the solar power industry, and the dyeing and finishing equipment segment, in which it manufactures and sell textile dyeing and finishing machines.
Forged Rolled Rings and Related Components Segment
The Company produces precision forged rolled rings and other forged components to the wind and other industries. Forged rolled rings and other forged components for the wind industry are used in wind turbines, which are used to generate wind power. It also manufactures shafts and forged rolled rings for gear rims, flanges and other applications. In addition to the wind industry, it sells its forged rolled rings and other forged components in other industries, inclu! ding heavy machinery manufacturing, petrochemical, metallurgical, sea port machinery, defense and radar manufacturing industries, which uses its forged rolled rings railway as components in the manufacture of equipment. It produces precision forgings using axial close-die forging technology, which is a technology for producing rotary precision forgings, using forging equipment, which it manufactured for its own use.
During the year ended December 31, 2011, the Company manufactured and delivered test subassemblies for solar cell manufacturing equipment, which marked its entry into the solar products market. It supplies solar components used in production of multi crystalline and mono crystalline silicon wafers. Solar industry capabilities include the manufacture of complex pressure vessels and chamber, high temperature vessels, and thick-walled vessels. Its forged rolled rings and other related products are sold for use by manufacturers of industrial equipment.< /p>
The Company competes with Wuxi Dachang Group.
Dyeing and Finishing Equipment Segment
Through the Company’s dyeing and finishing segment, it designs, manufactures and distributes a range of high and low temperature dyeing and finishing machinery. Its products feature both automation and mechanical-electrical integration. Its products are used in dyeing yarns, such as pure cotton, cotton-polyester, terylene, polyester wool, poly-acrylic fiber, nylon, cotton ramie, and wool yarn.
The Company competes with Fong’s National Engineering (Shenzhen) Co., Ltd.
- [By Roberto Pedone]
Another basic materials player that looks ready to trigger a major breakout trade is Cleantech Solutions (CLNT), which manufactures and sells high-precision forged rolled rings, yaw bearings and shafts. It also manufactures and sells textile dyeing and finishing machines. This stock is off to a strong start in 2013, with shares up 58%.
If you take a look at the chart for Cleantech Solutions, you’ll notice that this stock has been uptrending for the last two months and change, with shares moving higher from its low of $4.82 to its recent high of $7.04 a share. During that uptrend, shares of CLNT have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of CLNT within range of triggering a major breakout trade.
Traders should now look for long-biased trades in CLNT if it manages to break out above some near-term overhead resistance levels at $6.68 to $7.04 a share, and then once it takes out more resistance at $7.79 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 758,917 shares. If that breakout hits soon, then CLNT will set up to re-test or possibly take out its next major overhead resistance levels at $9 to $10 a share.
Traders can look to buy CLNT off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day at $5.67 a share, or around more support at $5 a share. One could also buy CLNT off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.